|
Post by tw12 on Jan 14, 2019 5:16:11 GMT -5
Dear Fellow Long-suffering MannKind Investors,
Good morning.
Here -- for us (anything but!) fools -- is a friendly reminder of a few facts in our financial favor:
* Our product, Technosphere, is inspired and disruptive technology. It’s astonishingly effective, proprietary for another ten years, and, in any case, extraordinarily difficult to reproduce.
* It has dozens of major marketplace applications.
* The initial market (diabtetics) is huge, worldwide, and growing rapidly.
* The duration of patient use is a lifetime.
* Substantial marketplace acceptance seems inevitable. Afrezza is gaining real traction; the second drug, Treprostinal, has a superb partner (United Therapeutics); and the rest of the line-up resonates with sophisticated and deep potential.
* Management is well experienced, hard working and, not least, dedicated to the extraordinary vision of Al Mann. In addition, it’s essentially a new team working for a new company; this helps to enhance focus and productivity.
* Promotion, while deficient these past few years, is easily fixed. In fact, Mike and his team are working hard to focus messaging much more effectively, beginning today.
* Even though efforts to disrupt the potential of the company have been incessant and pervasive -- both on the part of stock manipulators and of competitive businesses -- their influence will diminish against the overwhelming power of marketplace acceptance.
* And there is a world-class manufacturing facility in place in Danbury, ready and able to handle rapid growth.
So...MNKD seems indeed a wise investment, one that will offer not only inspired returns but also, most importantly, will enhance the lives of millions across the planet.
Now that's inspired medicine!
|
|
|
Post by falconquest on Jan 14, 2019 8:23:57 GMT -5
Dear Fellow Long-suffering MannKind Investors,
Good morning.
Here -- for us (anything but!) fools -- is a friendly reminder of a few facts in our financial favor:
* Our product, Technosphere, is inspired and disruptive technology. It’s astonishingly effective, proprietary for another ten years, and, in any case, extraordinarily difficult to reproduce.
* It has dozens of major marketplace applications.
* The initial market (diabtetics) is huge, worldwide, and growing rapidly.
* The duration of patient use is a lifetime.
* Substantial marketplace acceptance seems inevitable. Afrezza is gaining real traction; the second drug, Treprostinal, has a superb partner (United Therapeutics); and the rest of the line-up resonates with sophisticated and deep potential.
* Management is well experienced, hard working and, not least, dedicated to the extraordinary vision of Al Mann. In addition, it’s essentially a new team working for a new company; this helps to enhance focus and productivity.
* Promotion, while deficient these past few years, is easily fixed. In fact, Mike and his team are working hard to focus messaging much more effectively, beginning today.
* Even though efforts to disrupt the potential of the company have been incessant and pervasive -- both on the part of stock manipulators and of competitive businesses -- their influence will diminish against the overwhelming power of marketplace acceptance.
* And there is a world-class manufacturing facility in place in Danbury, ready and able to handle rapid growth.
So...MNKD seems indeed a wise investment, one that will offer not only inspired returns but also, most importantly, will enhance the lives of millions across the planet.
Now that's inspired medicine!
Does this post make you feel better?
|
|
|
Post by LongMNKD on Jan 14, 2019 9:19:03 GMT -5
No, The mere fact that we have people making motivational posts like this to lift spirits... thanks for the fresh bowl of kool-aid.
|
|
|
Post by itellthefuture777 on Jan 14, 2019 9:43:37 GMT -5
Dear Fellow Long-suffering MannKind Investors,
Good morning.
Here -- for us (anything but!) fools -- is a friendly reminder of a few facts in our financial favor:
* Our product, Technosphere, is inspired and disruptive technology. It’s astonishingly effective, proprietary for another ten years, and, in any case, extraordinarily difficult to reproduce.
* It has dozens of major marketplace applications.
* The initial market (diabtetics) is huge, worldwide, and growing rapidly.
* The duration of patient use is a lifetime.
* Substantial marketplace acceptance seems inevitable. Afrezza is gaining real traction; the second drug, Treprostinal, has a superb partner (United Therapeutics); and the rest of the line-up resonates with sophisticated and deep potential.
* Management is well experienced, hard working and, not least, dedicated to the extraordinary vision of Al Mann. In addition, it’s essentially a new team working for a new company; this helps to enhance focus and productivity.
* Promotion, while deficient these past few years, is easily fixed. In fact, Mike and his team are working hard to focus messaging much more effectively, beginning today.
* Even though efforts to disrupt the potential of the company have been incessant and pervasive -- both on the part of stock manipulators and of competitive businesses -- their influence will diminish against the overwhelming power of marketplace acceptance.
* And there is a world-class manufacturing facility in place in Danbury, ready and able to handle rapid growth.
So...MNKD seems indeed a wise investment, one that will offer not only inspired returns but also, most importantly, will enhance the lives of millions across the planet.
Now that's inspired medicine!
Yes a $300 million owned double award winning facility...at that..and a global award winning inhaler..that is free because it delivered insulin to efficently..with so much less residue..then any other..with studies that show no hypo's in all cases for type 2 in a zero carb study where they ate..nothing...and took Afrezza...with other clinicals showing superior glycemic control..and mimic of the healthy pancreas under 30 seconds..restoring that spike only seen in healthy individuals and leaves the body so fast..no need to eat for fear of hypos...no weight gain..no shot..no sight scaring..no need to daily titration..carb counting..leading KOL's say it halts the progression of diabetes...at some point..that alone..should wake people up...
|
|